Name
RF01-04 - Final results from the phase 2, open-label FOENIX-MBC2 study: efficacy and safety of futibatinib in adult patients with locally advanced/metastatic HR+/HER2− breast cancer harboring high-level FGFR1 gene amplification (China)
Date & Time
Wednesday, December 20, 2023
Speakers
Virtual Session Link